120-43-4

Basic information

• Product Name: Ethyl N-piperazinecarboxylate
• Synonyms: Ethyl 1-piperazinocarboxylate;Ethylcarbonyl piperazine;Ethyl N-pipperazinecarboxylate;1-PiperazinecarboxylicAcidEthylEtser99%(Gc);Ethyl 1-piperazinecarboxylate 98%;1-Piperazinecarboxylicacid,ethylester(6CI,7CI,8CI,9CI);N-CARBOETHYOXY PIPERAZINE aka ETHYL 1-PIPREAZINECA;ETHYL 1-PIPERAZINECARTOXYLATE
• CAS NO: 120-43-4
• Molecular Formula: C₇H₁₄N₂O₂
• Molecular Weight: 158.2
• EINECS: 204-395-2
• Product Categories: PIPERIDINE;Piperidines, Piperidones, Piperazines
• Mol File: 120-43-4.mol

Chemical Properties

• Melting Point: 120 °C
• Boiling Point: 273 °C(lit.)
• Flash Point: >230 °F
• Appearance: Clear light yellow/Oily Liquid
• Density: 1.08 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.0459mmHg at 25°C
• Refractive Index: n20/D 1.477(lit.)
• Storage Temp.: Store below +30°C.
• PKA: 8.50±0.10(Predicted)
• Water Solubility: soluble
• BRN: 125780
• CAS DataBase Reference: Ethyl N-piperazinecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl N-piperazinecarboxylate(120-43-4)
• EPA Substance Registry System: Ethyl N-piperazinecarboxylate(120-43-4)

Safety Data

• Hazard Codes: Xn,T
• Statements: 22-36/37/38-20/21/22
• Safety Statements: 23-24/25-37/39-26-36
• RIDADR: UN 2810 6.1/PG 3
• WGK Germany: 3
• RTECS: TL1378000
• TSCA: Yes
• HazardClass: 6.1(b)
• PackingGroup: III
• Hazardous Substances Data: 120-43-4(Hazardous Substances Data)

Usage

Chemical Properties

clear light yellow oily liquid

Uses

Intermediate.

InChI:InChI=1/C7H14N2O2/c1-2-11-7(10)9-5-3-8-4-6-9/h8H,2-6H2,1H3/p+1

Synthetic route

piperazine (110-85-0) + Diethyl carbonate (105-58-8) → 4-ethoxycarbonylpiperazine (120-43-4)

Conditions	Yield
at 80℃; for 3h;	98.5%

1-(ethylcarboxy)-4-benzylpiperazine (59325-12-1) → 4-ethoxycarbonylpiperazine (120-43-4)

Conditions	Yield
With hydrogen; palladium on activated charcoal In ethanol under 2206.5 Torr; for 4h;	78%

piperazine-1,4-dicarboxylic acid ethyl ester methyl ester → 4-ethoxycarbonylpiperazine (120-43-4)

Conditions	Yield
With L-Selectride In tetrahydrofuran at 20℃; for 48h;	69%

piperazine (110-85-0) + chloroformic acid ethyl ester (541-41-3) → 4-ethoxycarbonylpiperazine (120-43-4)

Conditions	Yield
In methanol; water at 0 - 25℃; for 4h;	33.7%
In methanol; water at 0 - 25℃; for 4h;	33.7%
bei pH 2.8-4.6;

bis-cyanomethyl-carbamic acid ethyl ester (86366-60-1) → 4-ethoxycarbonylpiperazine (120-43-4)

Conditions	Yield
With ethanol; nickel Hydrogenation;

O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate (205432-12-8) → 4-ethoxycarbonylpiperazine (120-43-4)

Conditions	Yield
With GLUTATHIONE; glutathione S-transferase P1-1 at 37℃; pH=7.4; Kinetics; Reagent/catalyst; Enzymatic reaction;

pentaerythritol tetraglycidylether (PETGE) + pentaerythritol tetraglycidyl ether (3126-63-4) → 4-ethoxycarbonylpiperazine (120-43-4)

Conditions	Yield
In methanol

piperazine (110-85-0) + ethyl 1-imidazolecarboxylate (19213-72-0) + piperazine dihydrochloride (142-64-3) → 4-ethoxycarbonylpiperazine (120-43-4)

Conditions	Yield
Stage #1: piperazine; piperazine dihydrochloride In water for 0.0833333h; Stage #2: ethyl 1-imidazolecarboxylate With sodium chloride In water for 0.5h; Stage #3: With sodium hydroxide In water chemoselective reaction;

tert-butyl 4-ethoxycarbonylpiperazine-1-carboxylate → 4-ethoxycarbonylpiperazine (120-43-4)

Conditions	Yield
With hydrogenchloride; water In dichloromethane at 20℃;
Stage #1: tert-butyl 4-ethoxycarbonylpiperazine-1-carboxylate With trifluoroacetic acid In dichloromethane at 0 - 20℃; Inert atmosphere; Stage #2: With ammonia In dichloromethane; water Inert atmosphere; Cooling;

O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate (205432-12-8) → 4-ethoxycarbonylpiperazine (120-43-4) + S-(2,4-dinitrophenyl)glutathione (26289-39-4)

Conditions	Yield
With glutathione-S-transferase; glutathion; d(TTTTTTTTAGGATCATGGTGATGCTCTACGTGCCGTAGCCTTTTTTTTT); calcium chloride; magnesium chloride for 0.166667h; pH=7.4; Enzymatic reaction;

methyl 4-benzylpiperazine-1-carboxylate → 4-ethoxycarbonylpiperazine (120-43-4)

Conditions	Yield
With palladium 10% on activated carbon; hydrogen In methanol at 40℃; for 48h;

4-ethoxycarbonylpiperazine (120-43-4) + propargyl bromide (106-96-7) → ethyl 4-(prop-2-yn-1-yl)piperazine-1-carboxylate (141403-43-2)

Conditions	Yield
With potassium carbonate In acetonitrile at 0℃; for 1.5h;	100%

4-ethoxycarbonylpiperazine (120-43-4) + teroxirone (2451-62-9) → carboxylate protected tris(2,3-epoxypropyl)isocyanurate

Conditions	Yield
In methanol; 1,2-dimethoxyethane at 25℃; for 51h;	100%

4-ethoxycarbonylpiperazine (120-43-4) + 4-[{4-chloro-2-[(2-chlorophenyl)(hydroxy)methyl]-phenyl}(2,2-dimethylpropyl)amino]-4-oxobutanoic acid (1292849-66-1) → ethyl 4-{4-[{4-chloro-2-[(2-chlorophenyl)(hydroxy)-methyl]phenyl}(2,2-dimethylpropyl)amino]-4-oxobutanoyl}-piperazine-1-carboxylate (1292849-78-5)

Conditions	Yield
With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; for 18h;	100%

4-ethoxycarbonylpiperazine (120-43-4) + Cbz-L-Gln (2650-64-8) → 4-((S)-2-benzyloxycarbonylamino-4-carbamoylbutyryl)piperazine-1-carboxylic acid ethyl ester (1021703-31-0)

Conditions	Yield
Stage #1: Cbz-L-Gln With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In tetrahydrofuran; dichloromethane at 20℃; for 0.0833333h; Stage #2: 4-ethoxycarbonylpiperazine In tetrahydrofuran; dichloromethane at 20℃; for 24h;	100%

4-ethoxycarbonylpiperazine (120-43-4) + (2R)-2-{[(benzyloxy)carbonyl]amino}-4-tert-butoxy-4-oxobutanoic acid (71449-08-6) → 4-((R)-2-benzyloxycarbonylamino-3-tert-butoxycarbonylpropionyl)piperazine-1-carboxylic acid ethyl ester

Conditions	Yield
Stage #1: (R)-2-(((benzyloxy)carbonyl)amino)-4-(tertbutoxy)-4-oxobutanoic acid With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine In tetrahydrofuran; dichloromethane at 20℃; for 0.25h; Stage #2: 4-ethoxycarbonylpiperazine In tetrahydrofuran; dichloromethane at 20℃; for 24h;	100%

3-chloromethyl-5-(2-fluoro-5-methyl-phenyl)-[1,2,4]oxadiazole (657424-58-3) + 4-ethoxycarbonylpiperazine (120-43-4) → 4-[5-(2-fluoro-5-methyl-phenyl)-[1,2,4]oxadiazol-3-ylmethyl]-piperazine-1-carboxylic acid ethyl ester

Conditions	Yield
With potassium carbonate In acetonitrile at 20℃;	99.1%

4-ethoxycarbonylpiperazine (120-43-4) + 7-Chloro-2-methoxy-4-trifluoromethyl-[1,8]naphthyridine (210643-01-9) → 4-(7-Methoxy-5-trifluoromethyl-[1,8]naphthyridin-2-yl)-piperazine-1-carboxylic acid ethyl ester (210643-02-0)

Conditions	Yield
With triethylamine at 100℃; for 24h;	98%

2-iodo-propane (75-30-9) + 4-ethoxycarbonylpiperazine (120-43-4) → ethyl 4-(1-methylethyl)piperazine-1-carboxylate (61014-91-3)

Conditions	Yield
With potassium carbonate In acetonitrile for 24h; Heating;	98%

4-ethoxycarbonylpiperazine (120-43-4) + C54H96N6O18S2 → C96H180N18O30S2

Conditions	Yield
In methanol at 20℃; for 24h;	98%

4-ethoxycarbonylpiperazine (120-43-4) + phenyl isothiocyanate (103-72-0) → ethyl 4-(phenylthiocarbamoyl)piperazine-1-carboxylate (332033-11-1)

Conditions	Yield
In diethyl ether for 0.5h;	98%
In benzene at 45℃; for 6h; Reflux;	85%

4-ethoxycarbonylpiperazine (120-43-4) + 5-chloro-3-methyl-1-phenyl-1H-pyrazole-4-carboxylic acid azide (1426433-94-4) → ethyl 4-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-ylcarbamoyl)piperazine-1-carboxylate

Conditions	Yield
In toluene for 1h; Curtius Rearrangement; Reflux;	98%

4-(1H-indazole-3-carboxamido)benzoic acid + 4-ethoxycarbonylpiperazine (120-43-4) → ethyl 4-[4-(1H-indazole-3-carboxamido)benzoyl]piperazine-1-carboxylate

Conditions	Yield
With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 20℃; for 16h;	98%

Upstream product

• 110-85-0 piperazine 
• 541-41-3 chloroformic acid ethyl ester 
• 86366-60-1 bis-cyanomethyl-carbamic acid ethyl ester 
• 59325-12-1 1-(ethylcarboxy)-4-benzylpiperazine 
• 205432-12-8 O²-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate 
• 3126-63-4 pentaerythritol tetraglycidyl ether 
• 19213-72-0 ethyl 1-imidazolecarboxylate 
• 142-64-3 piperazine dihydrochloride 
• 105-58-8 Diethyl carbonate 
• 219509-82-7 tert-butyl 4-ethoxycarbonylpiperazine-1-carboxylate 

Downstream Products

• 101354-80-7 4-(toluene-4-sulfonylmethyl)-piperazine-1-carboxylic acid ethyl ester 
• 59325-11-0 ethyl 4-methyl-1-piperazinecarboxylate 
• 856843-19-1 2-(4-ethoxycarbonyl-piperazino)-propionic acid ethyl ester 
• 63207-02-3 4-decyl-piperazine-1-carboxylic acid ethyl ester 
• 100957-07-1 4-(3,4-dichloro-phenacyl)-piperazine-1-carboxylic acid ethyl ester 
• 54041-93-9 1-(p-Methoxybenzhydryl)piperazine 
• 101889-42-3 4-[(2,4,6-trimethyl-phenylcarbamoyl)-methyl]-piperazine-1-carboxylic acid ethyl ester 
• 109511-69-5 4-[2-(N-ethyl-anilino)-ethyl]-piperazine-1-carboxylic acid ethyl ester 
• 102292-48-8 4-(3,4-dichloro-benzyl)-piperazine-1-carboxylic acid ethyl ester 
• 171609-72-6 1-(3,4-dichloro-benzyl)-piperazine; dihydrochloride 
• 59325-12-1 1-(ethylcarboxy)-4-benzylpiperazine 
• 55037-88-2 4-(4-methoxy-benzyl)-piperazine-1-carboxylic acid ethyl ester 
• 100723-38-4 4-benzoyl-piperazine-1-carboxylic acid ethyl ester 
• 13349-82-1 1-[2-(2-hydroxyethoxy)ethyl]piperazine 

Relevant articles and documents

L-selectride as a convenient reagent for the selective cleavage of carbamates

L-Selectride(R) was shown to selectively cleave methyl carbamates in the presence of more sterically demanding carbamates, including the selective cleavage of a methyl carbamate in the presence of an N-Boc group.

Synthesis, mechanistic studies, and anti-proliferative activity of glutathione/glutathione S-transferase-activated nitric oxide prodrugs

Nitric oxide (NO) prodrugs such as O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate (JS-K) are a growing class of promising NO-based therapeutics. Nitric oxide release from the anti-cancer lead compound, JS-K, is proposed to occur through a nucleophilic aromatic substitution by glutathione (GSH) catalyzed by glutathione S-transferase (GST) to form a diazeniumdiolate anion that spontaneously releases NO. In this study, a number of structural analogues of JS-K were synthesized and their chemical and biological properties were compared with those of JS-K. The homopiperazine analogue of JS-K showed anti-cancer activity that is comparable with that of JS-K but with a diminished reactivity towards both GSH and GSH/GST; both the aforementioned compounds displayed no cytotoxic activity towards normal renal epithelial cell line at concentrations where they significantly diminished the proliferation of a panel of renal cancer cell lines. These properties may prove advantageous in the further development of this class of nitric oxide prodrugs as cancer therapeutic agents.

Heteroaryl substituted dihydro pyrimidine compounds and their use in medicine

The invention relates to heteroaryl-substituted dihydropyrimidine compounds and application thereof in medicines, particularly application in medicines for treating and preventing hepatitis B. Particularly, the invention relates to compounds disclosed as general formula (I) or (Ia), or enantiomers, diastereoisomers, hydrates, solvates or pharmaceutically acceptable salts thereof, wherein the variables are defined in the specification. The invention also relates to application of the compounds disclosed as general formula (I) or (Ia), or enantiomers, diastereoisomers, hydrates, solvates or pharmaceutically acceptable salts thereof, especially application in medicines for treating and preventing hepatitis B.

Heteroaryl substituted dihydro pyrimidine compounds and their use in medicine

The invention relates to heteroaryl-substituted dihydropyrimidine compounds and application thereof in medicines, particularly application in medicines for treating and preventing hepatitis B. Particularly, the invention relates to compounds disclosed as general formula (I) or (Ia), or enantiomers, diastereoisomers, hydrates, solvates or pharmaceutically acceptable salts thereof, wherein the variables are defined in the specification. The invention also relates to application of the compounds disclosed as general formula (I) or (Ia), or enantiomers, diastereoisomers, hydrates, solvates or pharmaceutically acceptable salts thereof, especially application in medicines for treating and preventing hepatitis B.

A carbonyl group-containing modified multi-amine and its preparation method and its in the polyfunctional acrylate in the application of the

The invention relates to carbonyl-containing modified heterocyclic amine, a preparation method and application in multifunctional acrylic ester thereof. The carbonyl-containing modified heterocyclic amine is heterocyclic amine containing at least two ring structures, and is formed through carrying out ammonolysis reaction on carbonic ester and cycloaliphatic diamine, wherein the cycloaliphatic diamine is one or more selected from piperazine, isophorone diamine, 1, 4-hexamethylenediamine, 1-methyl-2, 4-diaminocyclohexane, N, N'-dimethyl-1 and 2-diaminocyclohexane. According to the application, when the carbonyl-containing modified heterocyclic amine is applied to multifunctional acrylic ester, the curing velocity of multifunctional acrylic ester is remarkably increased, the cure shrinkage rate of multifunctional acrylic ester is decreased, and the hardness and high temperature resistance of multifunctional acrylic ester are remarkably improved; and besides, the generated carbonyl-containing modified heterocyclic amine multifunctional acrylic ester has the characteristics of being light in smell, and small in amine mobility and less prone to yellowing.

BENZOPIPERIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES

A compound of formula I: (I) wherein: n is 1 or 2; p is 0 or 1; R1a, R1b, R1c and R1d are independently selected from H, halo, C1-4 alkyl, C1-4 fluoroalkyl, C3-4 cycloalkyl, C1-4 alkyloxy, NH-C1-4 alkyl and cyano; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2e is H or Me; R3a and R3b are independently selected from H and Me; R4 is either H or Me; R5 is either H or Me; R6a and R6b are independently selected from H and Me; A is either (IIa), where R7a is selected from N-linked N-containing C5-7 heterocycyl and (A); or (ii) (IIb), where X is selected from CH2, N H and O, one of R8a and R8b is selected from CI and ethoxy and the other of R8a and R8b is H.

Protein-protein communication and enzyme activation mediated by a synthetic chemical transducer

The design and function of a synthetic chemical transducer that can generate an unnatural communication channel between two proteins is described. Specifically, we show how this transducer enables platelet-derived growth factor to trigger (in vitro) the catalytic activity of glutathione-s-transferase (GST), which is not its natural enzyme partner. GST activity can be further controlled by adding specific oligonucleotides that switch the enzymatic reaction on and off. We also demonstrate that a molecular machine, which can regulate the function of an enzyme, could be used to change the way a prodrug is activated in a programmable manner.

CARBODITHIOATES WITH SPERMICIDAL ACTIVITY AND PROCESS FOR PREPARATION THEREOF

The present invention relates to the synthesis and biological evaluation of compound of formula I as spermicidal agents, and its pharmaceutically acceptable acid salt thereof. The invention provides bis(4- substituted-1-piperazinylthiocarbonyl) disulfide (when n = 0) and alkane-1,n-diylbis(4-substituted piperazine-1-carbodithioate) (when n = 0, 1, 2 or 3) as shown in figure 1 of the accompanying drawing. These compounds are found to be useful for spermicidal activity.

CDI-mediated monoacylation of symmetrical diamines and selective acylation of primary amines of unsymmetrical diamines

A highly efficient and green protocol for monoacylation of symmetrical diamines and chemoselective acylation of primary amines of unsymmetrical diamines has been developed.

Substituted phenoxypropyl-(R)-2-methylpyrrolidine aminomethyl ketones as histamine-3 receptor inverse agonists

Optimization of a series of aminomethyl ketone diamine H3R antagonists to reduce the brain exposure by lowering the pKa, led to molecules with improved pharmacokinetic properties. Compounds 9, 19, and 25 had high affinity for human H3R and demonstrated in vivo H3R functional activity in the rat dipsogenia model. Compound 9 displayed modest wake-promoting activity in the rat EEG/EMG model.